AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) shares were down 4.1% during trading on Tuesday . The company traded as low as $2.49 and last traded at $2.49. Approximately 114,529 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 2,386,285 shares. The stock had previously closed at $2.59.
Analyst Ratings Changes
Several research firms have recently commented on ABCL. Stifel Nicolaus decreased their price objective on AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, February 28th. KeyCorp lowered their price target on AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Finally, Benchmark reiterated a "hold" rating on shares of AbCellera Biologics in a research note on Monday, March 3rd.
Read Our Latest Analysis on ABCL
AbCellera Biologics Stock Down 2.1 %
The stock has a market capitalization of $688.35 million, a PE ratio of -3.79 and a beta of 0.45. The stock's 50 day moving average price is $2.86 and its 200-day moving average price is $2.82.
Institutional Trading of AbCellera Biologics
Several large investors have recently made changes to their positions in ABCL. Capital World Investors acquired a new position in shares of AbCellera Biologics during the fourth quarter valued at approximately $23,245,000. Two Sigma Investments LP grew its stake in shares of AbCellera Biologics by 28.6% in the fourth quarter. Two Sigma Investments LP now owns 3,257,311 shares of the company's stock worth $9,544,000 after acquiring an additional 723,676 shares in the last quarter. Two Sigma Advisers LP grew its holdings in AbCellera Biologics by 19.8% during the 4th quarter. Two Sigma Advisers LP now owns 2,608,400 shares of the company's stock worth $7,643,000 after acquiring an additional 430,800 shares in the last quarter. Tang Capital Management LLC raised its position in shares of AbCellera Biologics by 12.3% during the 4th quarter. Tang Capital Management LLC now owns 2,582,816 shares of the company's stock worth $7,568,000 after acquiring an additional 282,816 shares in the last quarter. Finally, Guardian Partners Inc. acquired a new position in AbCellera Biologics in the fourth quarter valued at $5,413,000. 61.42% of the stock is owned by hedge funds and other institutional investors.
About AbCellera Biologics
(
Get Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Recommended Stories
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
